On July 22, 2026, the U.S. Food and Drug Administration (FDA) granted historic **De Novo marketing authorization** to Johnson & Johnson MedTech for its **OTTAVA™ Robotic Surgical System**. This milestone marks the formal entry of the first table-integrated soft-tissue surgical robot into the American clinical market, directly challenging the twenty-five-year hegemony of standalone boom carts.

1. Authorized Clinical Indications

The initial FDA clearance spans high-volume general and bariatric surgical procedures:

  • Bariatric: Roux-en-Y gastric bypass, sleeve gastrectomy.
  • Upper GI & General: Gastrectomy, fundoplication, hiatal hernia repair, cholecystectomy, appendectomy, small-bowel resection, splenectomy, and lysis of adhesions.

The Zero-Footprint Architectural Innovation

"Unlike traditional systems where a dedicated multi-arm cart must be wheeled across the OR floor and locked into place, OTTAVA embeds its four robotic arms directly into the structure of the operating table. The arms stow invisibly beneath the tabletop until deployed, preserving total 360-degree patient access for surgical assistants and anesthesiologists."

2. Twin-Motion and Dynamic Table Repositioning

During complex abdominal surgery, gravity is routinely used to displace bowel loops away from the operative field via the Trendelenburg position. In legacy systems, adjusting table pitch required undocking all robotic trocars to prevent abdominal wall tearing. OTTAVA’s twin-motion kinematics synchronize robotic arm base coordinates in real time with motorized table tilt, enabling seamless intraoperative adjustments without interruption.

📚

Verified Primary Sources & Citations

Every empirical claim, economic metric, and technical assertion in this publication is cross-referenced against primary research literature and regulatory records: